Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension. In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.
Gold
J
J
Department of Medicine, Columbia University, College of Physicians & Surgeons, New York, New York, USA.
Cullinane
S
S
Chen
J
J
Seo
S
S
Oz
M C
MC
Oliver
J A
JA
Landry
D W
DW
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D001794:Blood Pressure / Q000187:drug effects; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007022:Hypotension / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D007275:Injections, Intravenous; D020105:Milrinone / Q000009:adverse effects* / Q000627:therapeutic use; D009200:Myocardial Contraction / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D012189:Retrospective Studies; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014667:Vasopressins / Q000008:administration & dosage / Q000627:therapeutic use*
D010726:Phosphodiesterase Inhibitors; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D020105:Milrinone